We previously reported outcomes after hypofractionated postprostatectomy radiotherapy (HYPORT) with a median follow-up of 32 months. This was a primary citation supporting the fractionation selection for NRG-GU003, which showed noninferiority of HYPORT versus conventional radiotherapy.

One hundred sixty-one consecutive patients with biochemically recurrent prostate cancer after prostatectomy underwent HYPORT from 2003 to 2013 at a single academic institution using image guided intensity modulated radiation therapy, with the majority (154 of 161) receiving 65 Gy in 26 fractions.

Median follow-up was 13.5 years. Forty-four patients (27.3%) experienced 58 late grade 3 to 5 toxicities (LTOX3) a median of 106 months after HYPORT. Fifty-five of 58 LTOX3 were genitourinary related. Higher-grade toxicities included 6 cystectomies and 3 deaths. At 2 years, only 2 patients had experienced an LTOX3. At 15 years, overall survival was 70%, freedom from biochemical recurrence was 52%, and the risk of LTOX3 was 34%.

Long follow-up is needed to fully capture severe toxicities after dose-escalated HYPORT. This should be considered prior to the broad adoption of similar regimens for this patient population with long survival potential.